LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a development stage
biopharmaceutical company, announced the initiation of a Phase II trial
of Puma's investigational drug PB272 (neratinib) for the extended
adjuvant treatment of breast cancer.
The 70 patient study will be an open label single arm Phase II trial of
PB272 monotherapy administered to patients with HER2-positive early
stage breast cancer who have previously received adjuvantmore...